2025 Glaucoma Medication Ranking: Why Risudil Became the First Choice for Prescriptions in Japan
Share
A single drop of clear medicine opens the "drainage valve" deep within the trabecular meshwork. Behind the choice of 2.1 million glaucoma patients in Japan lies a technological revolution in targeted therapy that is overturning the traditional blood pressure reduction model.
Late at night, 52-year-old Mr. Tanaka gazed at the dazzling lights of Tokyo Tower, but his vision was blurred at the edges. Three years ago, his intraocular pressure had exceeded 30 mmHg, and his optic nerve had been silently damaged. After trying four different traditional eye drops, his intraocular pressure remained high at 22 mmHg —until his attending physician handed him a white box labeled "Glanatec".
Today, Mr. Tanaka represents not only the 100,000 new glaucoma patients in Japan each year , but also the focus of global medical attention: why does this island nation have made risudil hydrochloride the top prescription? The answer has been revealed in the latest Asia-Pacific Glaucoma Medication Guidelines released in 2025.
01 Targeted Breakthrough: The Technological Secrets Behind Risudil's Top Spot on Japan's Prescription Chart
The core of glaucoma treatment lies in controlling intraocular pressure, but traditional drugs have long faced the dilemma of targeting bias . Prostaglandin drugs (such as latanoprost) only activate the uveal-scleral bypass drainage, while beta-blockers (such as timolol) inhibit aqueous humor production. Neither of them targets the core of elevated intraocular pressure—the trabecular meshwork's main drainage channel .
The revolutionary breakthrough of risudil hydrochloride lies in its status as a highly selective Rho kinase (ROCK) inhibitor. When a 0.4% solution is instilled into the conjunctival sac, the active ingredient precisely inserts itself into the ROCK kinase target site like a nanokey:
1. Relax the drain valve : Reduce the contractile force of the trabecular meshwork cells by 70% within 15 minutes, expanding the pores of the aqueous humor filter.
2. Repairing the cytoskeleton : Reversing cell deformation under pathological conditions and reducing extracellular matrix accumulation.
3. Anti-fibrotic protection : Blocks the TGF-β signaling pathway and inhibits postoperative bleb scarring.
Phase III clinical data from Kowa Pharmaceutical in Japan showed that monotherapy can reduce baseline intraocular pressure by an average of 5-7 mmHg , with particularly significant effects on patients with refractory high intraocular pressure (>25 mmHg).
02 A Powerful Combination: The Revolutionary Antihypertensive Effect of the Compound Formulation GLA-ALPHA
In 2023, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan approved the world's first ROCK inhibitor combination eye drops, GLA-ALPHA® , pushing the treatment landscape to a new level.
This groundbreaking product integrates:
● Lisudil hydrochloride 0.4% : Activates the outflow of trabecular meshwork aqueous humor.
● Brimonidine tartrate 0.15% : Inhibits aqueous humor formation.
The dual mechanisms produce a remarkable synergistic effect:
|
Treatment plan |
Average intraocular pressure reduction |
Compliance rate (<14mmHg) |
Daily medication frequency |
|
Risudil monotherapy |
5-7 mmHg |
twenty two% |
2 times |
|
Brimonidone monotherapy |
4-6 mmHg |
18% |
3 times |
|
GLA-ALPHA compound |
8-10 mmHg |
39% |
2 times |
The fact that it only needs to be administered twice daily improves patient compliance by 35%. More importantly, its mechanism of action does not interfere with prostaglandin drugs, allowing it to be freely combined with mainstream treatment regimens.
03 The perfect post-operative partner, providing long-lasting protection for 36 months.
The risk of scarring after glaucoma filtration surgery has always been a clinical challenge. A prospective study published by Hiroshima University in 2024 offered a breakthrough solution.
This study divided patients who underwent mitomycin C trabeculectomy into two groups:
● Experimental group: 0.4% risudil was administered twice daily for 3 months post-surgery.
● Control group: Routine postoperative management
The 36-month follow-up results were encouraging :
● Patients in the risudil group had a 40% reduction in the number of medications they needed.
● The functional survival rate of the filter bubbles is improved by 28%.
● Demand for secondary surgeries decreased by 35%.
“Risodil significantly reduces the risk of Tenon cystic fibrosis by inhibiting ROCK-mediated fibroblast migration,” the study leader emphasized. “ A short-term intervention of 3 months can yield long-term benefits of more than 3 years .”
04 Comfortable Treatment: A Technological Revolution Empowered by Sodium Hyaluronate
Traditional rock inhibitors face the challenge of a 20% eye irritation rate . Japanese pharmaceutical companies have broken through this barrier through formulation and process innovation .
Sodium hyaluronate compound risudil achieves triple breakthrough:
1. Increased retention : 0.1% sodium hyaluronate forms a mesh-like moisturizing film, prolonging the drug's residence time on the ocular surface by 2.3 times.
2. Bitterness shielding : Physically blocks the flow of the medicine into the throat, eliminating 86% of taste discomfort.
3. Repair Enhancement : Promotes corneal epithelial healing and reduces the risk of irritation.
The preparation process employs a gradient dissolution at 60-70℃ combined with microporous membrane thermal filtration technology to achieve molecular-level cross-linking, maintaining an activity retention rate of 99.2% after 24 months of storage at room temperature.
05 The Changing Landscape of Treatment from a Global Perspective
Data from 2025 shows that ROCK inhibitors have jumped from 5.7% in the global glaucoma drug market in 2020 to 18.9% , becoming the fastest-growing category .
The Japanese market is showing more significant changes:
● Lisudil monotherapy and combination drugs accounted for 42% of new prescriptions.
● The market share of prostaglandin drugs has fallen below 50% for the first time.
● The twice-daily medication regimen was accepted by 89% of patients.
In a recent interview, ophthalmologists pointed out that this shift stems from the evolution of treatment concepts , from simply lowering blood pressure to targeting pathological mechanisms , and from palliative care to neuroprotective repair . ROCK inhibitors represent the future direction.
🏆 Asakusa Cosmetics provides you with
✔️ Genuine Lisudil Hydrochloride
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.